Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
05/05/2008
Trade Name:
Argatroban
Generic or Proper Name (*):
argatroban
Indications Studied:
Heparin-Induced Thrombocytopenia (HIT) or HIT with Thrombosis
Therapeutic Category:
Hematology/Coagulation
Ages Studied:
0-16 years
Study #:
1
Study Type:
Efficacy/Safety/Pharmacokinetic/Pharmacodynamic
Study Design:
Open Label/Traditional Pharmacokinetic
No Patients:
11
No Centers:
12
No Countries:
1
BPCA(B), PREA(P):
B, P
Asian:
0
Black:
3
Other:
3
White:
12
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
-
-